-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Kg5nklMmUyrXZF4RQcXRUXTbrSYqi2zpLYoAW6AzjbCK+Loos732gQAIapnXUWYU
 l/92Vr0l3gq+aowzvB71BA==

<SEC-DOCUMENT>0000912057-02-026710.txt : 20020709
<SEC-HEADER>0000912057-02-026710.hdr.sgml : 20020709
<ACCEPTANCE-DATETIME>20020709123118
ACCESSION NUMBER:		0000912057-02-026710
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20020702
ITEM INFORMATION:		Changes in registrant's certifying accountant
FILED AS OF DATE:		20020709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		02698541

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a2084084z8-k.txt
<DESCRIPTION>FORM 8-K
<TEXT>
<PAGE>


                       SECURITIES AND EXCHANGE COMMISSION


                             WASHINGTON, D.C. 20549


                         -------------------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                       ----------------------------------



         Date of Report (DATE OF EARLIEST EVENT REPORTED): JULY 2, 2002
                                                           ------------


                            ANIKA THERAPEUTICS, INC.
- -------------------------------------------------------------------------------
               (EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)


<TABLE>
<S>                             <C>                        <C>
       MASSACHUSETTS                    000-21326                04-3145961
- -----------------------------   ------------------------    ------------------
(STATE OR OTHER JURISDICTION    (COMMISSION FILE NUMBER)        (IRS EMPLOYER
     OF INCORPORATION)                                      IDENTIFICATION NO.)
</TABLE>

               236 WEST CUMMINGS PARK, WOBURN, MASSACHUSETTS 01801
- -------------------------------------------------------------------------------
               (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)



                                 (781) 932-6616
                             ---------------------
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)



<PAGE>



     ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

     On July 2, 2002, Anika Therapeutics, Inc. (the "Company") selected
PricewaterhouseCoopers LLP as its principal independent auditor for the fiscal
year ending December 31, 2002. Arthur Andersen LLP served as the Company's
principal independent auditor for the fiscal years ended December 31, 2000 and
2001. The decision to engage PricewaterhouseCoopers LLP as the Company's new
principal independent auditor was recommended by the Audit Committee and
approved by the Company's Board of Directors.

     During the fiscal years ended December 31, 2000 and 2001 and the subsequent
interim period through June 6, 2002, PricewaterhouseCoopers LLP was not engaged
as either the principal accountant to audit the Company's financial statements
or as an independent accountant to audit any of the Company's consolidated
subsidiaries, nor was PricewaterhouseCoopers LLP consulted by the Company or
someone on its behalf with respect to either (i) the application of accounting
principles to any specific transaction, either completed or proposed, or the
type of audit opinion that might be rendered on the Company's financial
statements or (ii) any matter that was either the subject of a disagreement with
Arthur Andersen LLP or any reportable events described in Items 304(a)(2)(i) and
304(a)(2)(ii) of Regulation S-K, respectively.




<PAGE>


                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                          ANIKA THERAPEUTICS, INC.



Date: July 8, 2002                        /s/ Charles H. Sherwood
                                          -----------------------------------
                                          Charles H. Sherwood
                                          Chief Executive Officer and President


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
